フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
WINNERSH, England, Dec. 11 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS) today announced that it has started a Phase I...
WINNERSH, England, Nov. 21 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER)(NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development...
WINNERSH, England, Nov. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug...
WINNERSH, England, Nov. 2 /PRNewswire/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development...
WINNERSH, U.K., Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VER) (NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development...
WINNERSH, England, Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS) today announced that the U.S. Food and Drug...
- Vernalis Delivers on Significant Clinical Milestones and Establishes Commercial Operation - WINNERSH, England, Sept. 12 /PRNewswire-FirstCall/...
CHADDS FORD, Pa. and WINNERSH, U.K., July 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) and Vernalis plc...
WINNERSH, England, June 19 /PRNewswire-FirstCall/ -- Vernalis plc (NASDAQ:VNLS)(LSE:VER), a specialty bio-pharmaceutical and drug development...
NEW YORK, May 17 /PRNewswire-FirstCall/ -- The following is being issued by NASDAQ (NASDAQ:NDAQ): What: Simon Sturge, CEO of Vernalis plc...
Company Celebrates Significant Clinical Milestone WINNERSH, England, May 15 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS...
- Data to be Included as Part of Supplemental NDA to FDA - WINNERSH, England and CHADDS FORD, Pa., May 8 /PRNewswire-FirstCall/ -- Vernalis plc...
Endo Licenses Rights from Vernalis to Market Acute Migraine Treatment Frova(TM) CHADDS FORD, Pa., July 14 /PRNewswire-FirstCall/ -- Endo...
Vernalis Regains Control of North American Rights To Frovatriptan From Elan LONDON, March 30 /PRNewswire-FirstCall/ -- Highlights...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す